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A Weighted Genetic Risk Score of 
Adult Glioma Susceptibility Loci 
Associated with pediatric Brain 
tumor Risk
Maral Adel fahmideh  1,2*, Catharina Lavebratt  3, Giorgio tettamanti2, Joachim Schüz  4,  
Martin Röösli5,6, Kristina Kjaerheim7, Michael A. Grotzer8, Christoffer Johansen9,10, 
Claudia E. Kuehni11,12, Birgitta Lannering13, Lisbeth S. Schmidt14, Hatef Darabi15 & 
Maria feychting2
Genetic risk score (GRS) is used to demonstrate the genetic variants contributing to the polygenic 
architecture of complex diseases. By using a GRS, we have investigated the additive impact of the 
known adult glioma susceptibility loci on the pediatric brain tumor (pBt) risk and assessed the 
proportion of PBT heritability attributable to these susceptibility loci. A GRS was generated for PBTs 
based on the alleles and associated effect sizes derived from a previously published genome-wide 
association study on adult glioma. The GRS was calculated in CEFALO, a population-based case-
control study of brain tumors in children and adolescents including saliva DNA of 245 cases and 489 
controls. The unconditional logistic regression model was used to investigate the association between 
standardized GRS and risk of PBTs. To measure the variance explained by the effect of GRS, Nagelkerke 
pseudo-R2 was calculated. The GRS for adult brain tumors was associated with an increased risk of PBTs 
(OR 1.25 [95% CI 1.06–1.49], p = 0.009) and 0.3% of the variance in PBTs could be explained by the 
effect of GRS on the liability scale. This study provides evidence that heritable risks of PBTs are in-part 
attributable to some common genetic variants associated with adult glioma.
Genetic risk score (GRS), or polygenetic risk score, calculations are used to analyze the oligo- or polygenic archi-
tecture underlying complex genetic disorders. In such calculations, first, the alleles which are associated with a 
trait at a certain threshold and their effect sizes are identified in a discovery sample. Then, a GRS, being a compos-
ite score of the alleles identified in the discovery sample and weighted by the effect size (e.g. log odds ratio (OR)), 
is calculated for each individual in an independent target sample. Later, the regression model is applied to assess 
the association between the GRS and the phenotype in the target sample adjusting for covariates1.
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The current study aimed to examine whether the genetic risk score for adult brain tumors, taking into account 
the combined effect of five susceptibility loci, is associated with risk of pediatric brain tumors and to assess the 
proportion of pediatric brain tumor heritability attributable to these known adult glioma susceptibility loci.
Methods
We generated the GRS for pediatric brain tumors based on the alleles and associated effect sizes derived from 
a previously published genome-wide association study (GWAS) on adult glioma2, which in turn was based on 
the meta-analysis of six previously published GWAS and also two new GWAS including in total 12496 cases and 
18190 controls. Quality control procedures and the GWAS results were described in details in the original paper2. 
The CEFALO study was employed as the target sample. CEFALO is a population-based case-control study of brain 
tumors in children and adolescents aged 7–19 years conducted in Sweden, Denmark, Norway, and Switzerland. 
Details of the study methods, single nucleotide polymorphism (SNP) selection, genotyping, and the quality con-
trol procedures have been described previously3–5. Briefly, saliva DNA of 245 cases and 489 controls was included 
in the study and was satisfactorily genotyped for 92 SNPs. The study was approved by the national data protec-
tion boards and ethical committees in all participating countries, all research was performed in accordance with 
relevant guidelines/regulations and written informed consent was obtained from all participants and/or their 
parents. Table 1 summarizes demographic characteristics of included cases and controls and the distributions of 
diagnostic pediatric brain tumor types. We selected the discovery sample for these analyses based on its similarity 
with the target sample for ethnicity, as well as its large sample size leading to the more accurate reported estimates.
SNPs which were associated with the adult glioma risk at the genome-wide significance level in all the discov-
ery, validation and combined results of either all glioma or non-glioblastoma glioma in the discovery sample were 
selected for the GRS analyses. Thus, the GRS in the CEFALO study was based on 5 SNPs (rs6010620, rs2736100, 
rs4977756, rs498872, rs2297440) and corresponding to the number of the risk alleles weighted by the logarithm 
of the ORs from the discovery sample across this set of SNPs (Table 2). PLINK was used to perform the analyses6.
The GRS was subsequently standardized using its mean value and standard deviation (SD); for which the OR 
associated with it can then be interpreted as the increased (or decreased) odds of pediatric brain tumors for a one 
SD change in GRS. The unconditional logistic regression model was applied to evaluate whether the standardized 
GRS is associated with the risk of pediatric brain tumors adjusted for age, sex and country as covariates (full 
Characteristics Cases Controls
No. of participants 245 489
Sex
Males 136 (56%) 261 (53%)
Females 109 (44%) 228 (47%)
Age-group (at reference date)
7–9 years old 48 (20%) 112 (23%)
10–14 years old 108 (44%) 219 (45%)
15–19 years old 89 (36%) 158 (32%)
Country
Sweden 106 (43%) 174 (36%)
Norway 24 (10%) 62 (13%)
Denmark 62 (25%) 134 (27%)
Switzerland 53 (22%) 119(24%)
Type of tumor (ICCC-3 group III)a
Astrocytoma (IIIb) 134 (55%)
Other gliomas (IIId) 20 (8%)
Ependymoma (IIIa) 19 (8%)
Intracranial embryonal tumors (IIIc) 7 (3%)
Other specified intracranial neoplasms (IIIe) 49 (20%)
Unspecified intracranial neoplasm (IIIf) 16 (6%)
Table 1. Characteristics of cases and controls. aRestricted to ICD-O-3 location C71; patients with 
neurofibromatosis and tuberous sclerosis were excluded.
SNP Chr. Gene Location (bp) Risk allele Ref allele OR 95% CI P value
rs2736100 5 TERT 1339516 C A 1.29 1.25–1.34 2.34 × 10−45
rs4977756 9 CDKN2A/B 22058652 G A 1.28 1.23–1.32 1.46 × 10−41
rs498872 11 PHLDB1 117982577 A G 1.14 1.10–1.18 4.09 × 10−11
rs6010620 20 RTEL1 61780283 G A 1.34 1.29–1.40 2.81 × 10−40
rs297440 20 RTEL1 62312299 C T 1.36 1.30–1.42 1.60 × 10−42
Table 2. Summary results of the discovery sample for the SNPs included in genetic risk score analyses2.
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model); unmatched analyses have been performed since not all CEFALO participants provided saliva sample. To 
measure the variance explained by the effect of GRS, Nagelkerke pseudo-R2 was calculated as the difference of 
R2 in the full model compared to the reduced model including the covariates but not the GRS. The analyses were 
conducted using R7.
The study was approved by the Ethical Review Board in Stockholm, Sweden.
Results
The results indicated that the standardized genetic risk score for adult brain tumors was associated with increased 
risk of pediatric brain tumors (OR 1.25 [95% CI 1.06–1.49], p = 0.009). The identified OR of 1.25 can be inter-
preted as: one SD increase in GRS is associated with a 25% increased odds of pediatric brain tumors. Moreover, 
1.2% of the variance in pediatric brain tumors could be explained by the effect of the GRS (R2 = 0.012). The 
estimated disease prevalence used to transform the estimated heritability to the liability scale was 0.04%. The 
SNP-heritability on the liability scale was estimated to be 0.003.
The minimum detectable ORs for each individual SNPs rs6010620 (G), rs2736100 (C), rs4977756 (G), 
rs498872 (A), and rs2297440 (C) in this dataset of 245 cases and 489 controls were 1.61, 1.56, 1.56, 1.58, and 1.62, 
respectively.
Discussion
This study was performed based on the hitherto largest series of pediatric brain tumor cases with the purpose to 
investigate the additive impact of the known adult glioma susceptibility loci on pediatric brain tumor risk and for 
the first time to investigate the similarity of SNP-heritability between adult and pediatric brain tumors.
To our knowledge, to date, two studies have assessed the heritability of adult glioma based on the known 
glioma susceptibility loci. Sampson et al. assessed the adult glioma heritability based on 10 loci (rs1412829, 
rs2157719, rs2736100, rs2853676, rs4295627, rs4809324, rs4977756, rs498872, rs6010620, rs891835) and 
reported the estimated SNP-heritability of 1.7% (h2 = 0.017)8. Moreover, Kinnersley et al. investigated the pro-
portion of glioma heritability attributable to known glioma susceptibility loci (rs2736100, rs11979158, rs2252586, 
rs4295627, rs4977756, rs498872, rs6010620) and the estimated proportion of genetic variance of adult glioma 
explained by these seven risk loci was 1.6%9.
In the present study, we estimated that 0.3% of the variance in the pediatric brain tumors could be explained 
by the effect of the genetic risk score containing five known adult glioma susceptibility loci. This provides evi-
dence that the heritable risks of pediatric brain tumors are in-part attributable to some common genetic variants 
associated with adult glioma. Also, previously, based on CEFALO study, we could show that adult and pediatric 
brain tumors have some genetic risk factors in common4,5. However, more polygenic analyses based on large 
sample sizes and big genotyping data for both adult and pediatric brain tumors are required to determine the 
similarity of genetic architecture in adult and pediatric brain tumors which is clinically relevant from a risk pre-
diction and treatment perspective. In addition, this line of research provides the basis to develop comprehensive 
risk prediction models including both genetic and environmental factors for brain tumors that eventually may 
lead to brain tumor prediction and prevention. This can be achieved by incorporating large collaborative genetic 
association studies and high quality registration data and could be leveraged by refinement of molecular classifi-
cation and development of somatic characteristics of brain tumors10.
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